OVID News and Press, Ovid Therapeutics Inc. From 11/12/20

Ovid Therapeutics (OVID): Q3 GAAP EPS of -$0.28 beats by $0.14.Revenue of $6.9M beats by $6.82M.Cash and cash equivalents of $86.9M.Shares -2.4%.Press Release For further details see: Ovid Therapeutics EPS beats by $0.14, beats on revenue

On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020 Reported positive ELEKTRA results; Ovid and Takeda plan to initiate phase 3 registrational program of OV935/TAK935 (soticlestat) in Dravet Syndrome and Lennox-Gastaut syndr...

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced it will host an educational webinar on Thursday, October ...

Four abstracts from the OV101 (gaboxadol) clinical development program in Angelman Syndrome and Fragile X Syndrome to be presented NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines th...

Ovid Therapeutics (OVID) reported results from Phase 2 ARCADE and ENDYMION studies evaluating soticlestat (OV935/TAK-935) in patients with CDKL5 deficiency disorder ((CDD)) and Dup15q syndrome (Dup15q), two rare developmental and epileptic encephalopathies. Data from both the studie...

Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time In CDD patients, median motor seizure frequency reduction was 24% in...

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fitzgera...

Shares of GW Pharmaceuticals (NASDAQ: GWPH) have been sliding since the company reported quarterly results that were arguably positive. Even though GW Pharmaceuticals reported second-quarter product sales that grew 70% year over year, its stock price has tumbled about 20% since announci...

Since my last article on Ovid Therapeutics ( OVID ) the stock has increased almost 5-fold, breaking through the $9 ceiling at one point. Just last week, the stock saw some strong surge before what turned out to be successful phase 2 data from a drug called soticlestat in children with Dravet s...

Altimmune provides positive updates for AdCOVID Altimmune Inc. ( ALT ) reported positive data from the preclinical studies of its lead vaccine candidate, AdCOVID. The company is carrying out these studies as part of its collaboration with the University of Alabama at Birmingham for dev...